Jahresbericht 2018 für

LS2 Life Sciences Switzerland: Life Sciences Switzerland


Präsident/Präsidentin: Urs Greber, University of Zurich

Von: Carolin von Schoultz, carolin.vonschoultz@ls2.ch

Zusammenfassung


 

The LS2 Annual Meeting is mostly financed by the participants, sponsors and exhibitors. However, some key activities have been made possible with the support of SCNAT, including the support to BSc/MSc students to attend the meeting and support of the extremely successful PIs of Tomorrow - The Future of Swiss Research Postdoc competition.



Publikationen


Chimia (Aarau). 2018 Nov 30;72(11):817-818. doi: 10.2533/chimia.2018.817.

The Partnership of DMCCB and LS².

von Schoultz C1, Heinis C2, Auberson Y3.

Author information

1 Life Sciences Switzerland, House of Academies, Laupenstrasse 7, CH-3001 Bern;, Email: carolin.vonschoultz@ls2.ch.

2 Institute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne.

3 Novartis Institutes for BioMedical Research, WKL-136.6.82, Klybeckstrasse 141, CH-4057 Basel.



Tagungen / Kurse


LS2 Annual Meeting 2018

Section Meetings

LS2 Satellite Meetings for young scientists preceding or following the conferences below, with kind support from SCNAT:

 

Co-organized meetings

 

 

 



Internationale Aktivitäten


B) institutionelle Zusammenarbeit: Delegationen an Kongresse und administrativen Sitzungen von internationalen Dachorganisationen (Personen, Anlass, Gremium).



Nachwuchsförderung




Forschungsunterstützende Informations- und Koordinationsaufgaben




Dialog mit der Gesellschaft


Booth at Planète Santé, Palexpo Geneva, 4-7 October 2018

https://www.planetesante.ch/salon/

After the great success of the 2016 edition, LS2 ran a booth again at Planète Santé 2018! We closely collaborated with SimplyScience.ch to realize the booth at the fair among 30.000 visitors. The booth was kindly supported by SCNAT.

 

 

Free Public Panel Discussion: A Transdisciplinary Panel on CRISPR/Cas9

A FEBS Science & Society-funded Science Policy Session

as part of the LS2 Annual Meeting 2018 in Lausanne

13.02.2018, 10:30-12:30, University of Lausanne

The CRISPR/Cas9 revolution is widely being talked about these days. Apart from being a major scientific breakthrough, it also reveals how different fears and hopes are being handled by science, society, economy, and policy makers. The CRISPR/Cas9 system thus represents an ideal case to discuss the different implications of modern biomedical research, from economical, legal and ethical implications, to aspects of scientific impact and careers. The transdisciplinary panel gave the stage to experts from different fields to then discuss all these aspects around one technology.

with: 

Martin Jinek (University of Zurich), Bruno Lemaitre (EPF Lausanne), Effy Vayena (Chair of Bioethics, Health Ethics and Policy Lab, Department of Health Sciences and Technology, ETH Zurich), Heinz Müller (Swiss Federal Institute of Intellectual Property, Bern)

Moderation: Nik Walter (Tages-Anzeiger/SonntagsZeitung)